To compare the SPF10 system to the GP5+/6+ system for high risk HPV (hrHPV) screening on cervicovaginal samples in Nigeria.
In Karu, a suburban district of Abuja, Nigeria, 400 women were randomized for a self- or hospital-collection after flyer recruitment. A volume of 250 μL was used for DNA isolation with the MagNA Pure and 750 μL was used for nucliSENS easyMAG isolation. MagNA Pure isolates were tested with the SPF10-PCR-DEIA-LiPA25, version 1 system, a test often used in epidemiological studies. GP5+/6+-PCR-EIA, a clinically validated cervical cancer screening method, followed by Luminex genotyping was performed on the nucliSENS easyMAG isolate. qPCR was done (RNaseP) to assess the level of human DNA.
Samples of 298 women (74.5% response), with a mean age of 41.1 (SD 7.8, Range 30–62) years were included. The SPF10 showed 23.8% hrHPV+ versus 10.4% with the GP5+/6+. The SPF10 found 9 (3%) samples positive for HPV genotype 16 or 18 versus 4 (1%) by GP5+/6+. Comparing HPV genotypes identified by both systems, 22/29 (75.9%) had concordant genotypes, with the SPF10 system finding additional (low risk) genotypes.
Cervical cancer screening by hrHPV testing seems feasible in Nigeria. Corresponding with previous studies (Hesselink et al, 2008), the level of hrHPV+ found by SPF10 was higher compared to GP5+/6+. HrHPV genotyping with both systems showed good agreement. To assess the clinical relevance of any hrHPV+ result, a follow-up study collecting a colposcopy directed biopsy and a repeat hrHPV test is being performed. Results are expected by September 2015.